Rapid point-of-care test for hepatitis B core-related antigen to diagnose high viral load in resource-limited settings

Yusuke Shimakawa, Gibril Ndow, Atsushi Kaneko, Katsumi Aoyagi, Maud Lemoine, Yasuhito Tanaka, Prolifica Hbcrag-Rdt Study Group

▶ **To cite this version:**

Yusuke Shimakawa, Gibril Ndow, Atsushi Kaneko, Katsumi Aoyagi, Maud Lemoine, et al.. Rapid point-of-care test for hepatitis B core-related antigen to diagnose high viral load in resource-limited settings. Clinical Gastroenterology and Hepatology, WB Saunders, In press, 10.1016/j.cgh.2022.05.026 . pasteur-03697822

HAL Id: pasteur-03697822

https://hal-pasteur.archives-ouvertes.fr/pasteur-03697822

Submitted on 17 Jun 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution| 4.0 International License

Journal Pre-proof



Rapid point-of-care test for hepatitis B core-related antigen to diagnose high viral load in resource-limited settings

Yusuke Shimakawa, Gibril Ndow, Atsushi Kaneko, Katsumi Aoyagi, Maud Lemoine, Yasuhito Tanaka, PROLIFICA/HBcrAg-RDT Study Group

PII: S1542-3565(22)00554-7
DOI: https://doi.org/10.1016/j.cgh.2022.05.026
Reference: YJCGH 58503

To appear in: *Clinical Gastroenterology and Hepatology*
Accepted Date: 13 May 2022

Please cite this article as: Shimakawa Y, Ndow G, Kaneko A, Aoyagi K, Lemoine M, Tanaka Y, PROLIFICA/HBcrAg-RDT Study Group, Rapid point-of-care test for hepatitis B core-related antigen to diagnose high viral load in resource-limited settings, *Clinical Gastroenterology and Hepatology* (2022), doi: https://doi.org/10.1016/j.cgh.2022.05.026.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 by the AGA Institute

Title

Rapid point-of-care test for hepatitis B core-related antigen to diagnose high viral load in resource-limited settings

Authors

Yusuke Shimakawa,[1,2] Gibril Ndow,[3,4] Atsushi Kaneko,[5] Katsumi Aoyagi,[5] Maud Lemoine,[4] Yasuhito Tanaka,[6] and PROLIFICA/HBcrAg-RDT Study Group

Affiliations

[1] Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur, Paris, France

[2] International Research Center for Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan

[3] Medical Research Council (MRC) Unit The Gambia at the London School of Hygiene & Tropical Medicine, Fajara, The Gambia

[4] Department of Metabolism, Digestion & Reproduction, Imperial College London, UK

[5] Research and Development Division, Fujirebio Inc., Tokyo, Japan

[6] Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan

Contributors

Théo Cerceau,[1] Amie Ceesay,[2] Akira Hasegawa,[3] Naoki Yamamoto,[3] Jeanne Perpétue Vincent,[1] Takehisa Watanabe,[4] Masaya Baba,[5] Bakary Sanneh,[6] Ignatius Baldeh,[6] Ramou Njie,[7,8] Umberto D'Alessandro,[2] Maimuna Mendy,[9] Isabelle Chemin,[10] and Mark R. Thursz[11]

Journal Pre-proof

[1] Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur, Paris, France

[2] Medical Research Council (MRC) Unit The Gambia at the London School of Hygiene & Tropical Medicine, Fajara, The Gambia

[3] Research and Development Division, Fujirebio Inc., Tokyo, Japan

[4] Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan

[5] International Research Center for Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan

[6] National Public Health Laboratories, Ministry of Health, The Gambia

[7] Edward Francis Small Teaching Hospital, Banjul, The Gambia

[8] School of Medicine & Allied Health Sciences, University of The Gambia

[9] International Agency for Research on Cancer (IARC), Lyon, France

[10] INSERM U1052, CNRS UMR5286, Centre de Recherche en Cancérologie, Université Claude Bernard, Lyon, France

[11] Department of Metabolism, Digestion & Reproduction, Imperial College London, UK

Journal Pre-proof

Running Title

Rapid diagnostic test for HBcrAg

Conflict of Interest

AK, AH, NY, and KA are employees of Fujirebio Inc. YS and ML received research grants from Gilead Sciences. The other authors declare no conflict of interest.

Data Sharing

Individual participant data will not be made publicly available, since data contain protected health information. However, deidentified participant data may be shared upon reasonable request if this was approved by the scientific committee of the PROLIFICA Programme.

Financial Support

This work was supported by the Gambian Ministry of Health, MRC Unit The Gambia at LSHTM, the European Commission [FP7 grant 265994], the Viral Hepatitis Research Foundation of Japan, JSPS KAKENHI Grant Number JP21K10416, and the grant-in-aid from the Research Program on Hepatitis from the Japan Agency for Medical Research and Development (AMED JP21fk0310101).

Corresponding Author

Yusuke Shimakawa

Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur, 25-28 rue du Dr Roux, 75015 Paris, France

Phone: +33 (0) 1 40 61 38 87

Fax: +33 (0) 1 45 68 88 76

Email: yusuke.shimakawa@pasteur.fr

Authors' Contributions

Journal Pre-proof

Study concept and design, YS, YT; acquisition of data, YS, GN, AC, AK, AH, NY, KA, ML; analysis and interpretation of data, YS, TC, AK, KA, JPV, ML, YT; drafting of the manuscript, YS, TC; critical revision of the manuscript for important intellectual content, all authors; statistical analysis, YS, TC; obtained funding, YS, BM, MRT, ML, YT; administrative, technical, or material support, AT, AH, NY, KA; study supervision, YS, TW, BS, IB, RN, UDA, MM, IC, MRT, ML, YT.

Word count

1,500 words (including 685 words for describing methods)

Number of Tables

One

Number of Figures

None

Number of Supplementary Materials

Two (one figure and one table)

Journal Pre-proof

Keywords

Hepatitis B core-related antigen; point-of-care tests; validation studies; sensitivity and specificity; Africa; elimination

Journal Pre-proof

Global elimination of hepatitis B virus (HBV) requires scale-up of testing and treatment services in low-income and middle-income countries (LMICs). Following the screening for HBV surface antigen (HBsAg), quantification of serum HBV DNA is invariably required to identify a subset of HBV-infected individuals who should immediately start antiviral therapy. Anti-HBV treatment is recommended for patients with chronic HBV infection (CHB) who have high HBV DNA levels (≥2,000 or ≥20,000 IU/ml) in the presence of liver fibrosis or inflamation.[1–3] To prevent mother-to-child transmission (MTCT), antiviral prophylaxis is recommended for HBV-infected pregnant women with high viremia (≥200,000 IU/ml).[1,2,4] Despite its central role in the clinical management of CHB, >95% of HBV-infected people live in LMICs where HBV DNA quantification is not easily accessible.

HBV core-related antigen (HBcrAg) may be an effective alternative to quantifying HBV DNA in treatment-naïve CHB patients due to its close correlation with intrahepatic covalently closed circular DNA levels[5] and serum HBV DNA levels.[6] Indeed, maternal HBcrAg levels during pregnancy accurately predicted MTCT events despite infant immunization.[7] However, its measurement requires chemiluminescence enzyme immunoassay (CLEIA), which remains unavailable in decentralized settings in LMICs. We, therefore, developed a rapid diagnostic test based on immunochromatography enabling to detect HBcrAg (HBcrAg-RDT) at the point of care and performed the analytical/clinical validation.

HBcrAg-RDT is a lateral flow assay using anti-HBcrAg monoclonal antibodies. A test kit contains a single-use disposable plastic cassette, pretreatment solution, neutralizing solution, squeeze tube, and applicator tip (Supplementary Figure). No special equipment is required. First, 50 μL of the

Journal Pre-proof

sample was mixed with 150 µL of pretreatment solution containing acid, detergents, and reducing agent. After leaving for 10 minutes at room temperature, 50 µL of neutralizing solution, containing buffer, detergent, and base, was added. Subsequently, 20 µL of the pretreated sample was applied to the sample window of the cassette. On the sample pad, HBcrAg in the pretreated sample was bound to primary antibodies conjugated with alkaline phosphatase (ALP). These antigen-antibody complexes then migrated to the interpretation window where they were captured by secondary anti-HBcrAg antibodies immobilized on the test line, forming sandwich immune complexes. Meanwhile, free ALP-labeled antibodies further migrated to the control line, where they were captured by anti-ALP antibodies immobilized on this line. Whenever ALP was captured on the test line or control line, a blue color appeared with a chromogenic substrate that had migrated with a developing solution precontained in the cassette.

Journal Pre-proof

Analytical validation was performed at Fujirebio Hachioji Laboratory, Japan, using three types of reference materials (serum/plasma/whole blood) in which HBcrAg levels were quantified by a reference CLEIA (LUMIPULSE G1200, Fujirebio). Using serially diluted concentrations of HBcrAg-CLEIA, the limit of detection (LoD) was defined as the lowest concentration detected in ≥95% of 20 replicates. Inter- and intra-operator reproducibility were evaluated by three operators over one day and by a single operator over three days, respectively, using three types of sera: high-positive (5.0 $\log_{10}$ U/mL), low-positive (4.0 $\log_{10}$ U/mL), and negative. Analytical specificity was evaluated by spiking low-positive sera (4.2 $\log_{10}$ U/mL) and negative control with potentially interfering substances (Interference Check A plus/RF plus, Sysmex, Japan). Operating temperature was evaluated at 18/20/25/30/37/39 °C using low-positive and negative sera. Stability of HBcrAg after sample pretreatment was assessed by leaving pretreated sera/plasma/whole blood with two

Journal Pre-proof

different HBcrAg-CLEIA levels (low-positive (4.2 $\log_{10}$ U/mL) or negative) at a constant temperature of 4 °C or 25 °C for 0/1/3/7 days. Effects of freeze/thaw cycles were evaluated using five freshly-collected positive sera (range: 3.6-6.9 $\log_{10}$ U/mL) at four different time points: before freezing, after one, two, and three freeze/thaw cycles (-60 °C).

We previously reported the performance of HBcrAg-CLEIA in 284 treatment-naïve CHB patients from the PROLIFICA cohort in The Gambia, West Africa.[8] Using the exact same cohort, we evaluated this time the performance of HBcrAg-RDT to diagnose three clinically important HBV DNA thresholds (≥2,000/≥20,000/≥200,000 IU/ml) and three corresponding HBcrAg levels (≥3.6/≥4.5/≥5.3 $\log_{10}$ U/mL).[6] Additionally, we assessed 75 HBsAg-negative Gambians (HCV-infected: 12%, HIV-infected: 7%) as HBV-negative control (13 HCC, 24 cirrhotic, 38 without liver disease). HBeAg and HBV DNA were tested locally by enzyme immunoassay (EIA, ETI-EBK Plus, Diasorin, Italy) and in-house RT-PCR (LoD: 50 IU/ml), respectively. Stored sera (-80 °C) were sent to Toshiba General Hospital, Japan. HBcrAg-CLEIA and HBcrAg-RDT were tested by staff masked to the clinical/virological data.

Journal Pre-proof

We also evaluated the accuracy of simplified HBV DNA-free algorithms using HBcrAg-RDT to identify HBV-infected individuals eligible for antiviral therapy. As a reference method, we referred to each of the eligibility criteria, established by the American (AASLD), European (EASL), and Asian Pacific (APASL) guidelines. All of these considered HBV DNA levels, HBeAg, alanine transaminase (ALT), and liver histopathology or FibroScan.[1–3] We developed three simplified algorithms. Model 1 was the same as the reference criteria (AASLD/EASL/APASL) except that HBV DNA was replaced with HBcrAg-RDT (positive

HBcrAg-RDT indicating viremia of ≥2,000 or ≥20,000 IU/mL) and histopathology was replaced with FibroScan. Model 2 consisted only of HBcrAg-RDT and ALT, a simple scoring system similar to the TREAT-B, composed of HBeAg and ALT.[9] The total score was obtained by adding HBcrAg-RDT score, negative (±0) or positive (+1), and ALT score, <20 IU/L (±0), 20-39 (+1), 40-79 (+2) or ≥80 (+3). The total score ≥2 indicated the eligibility.[9] Model 3 only used HBcrAg-RDT: positive indicated eligible and negative indicated ineligible. Statistics were performed using Stata 16.0 (Stata Corporation, USA). The study was approved by the Gambian Government/MRC Joint Ethics Committee.

Using HBcrAg-CLEIA as a reference, the LoD of HBcrAg-RDT was 4.3 $\log_{10}$ U/mL for serum and plasma and 4.9 $\log_{10}$ U/mL for whole blood (Supplementary Table). Complete agreement was observed for both the inter- and intra-operator reproducibility. HBcrAg-RDT results were not affected by the addition of haemolysis (470 mg/dL), lipaemia (1630 mg/dL), unconjugated bilirubin (19.9 mg/dL), conjugated bilirubin (20.1 mg/dL), or rheumatoid factor (50 mg/dL). The operating temperature was confirmed to be at least 18-39 °C. HBcrAg stability in pretreated serum/plasma/whole blood was preserved for at least 7 days at both storage temperatures (4 and 25 °C). HBcrAg-RDT results in the five freshly-collected sera remained unchanged after up to three freeze/thaw cycles.

In 75 HBsAg-negative Gambians, none tested positive for HBcrAg-RDT, giving a specificity of 100% (95%CI: 95.2-100) in the HBsAg-negative population. As reported in our previous article,[8] in 284 HBsAg-positive Gambians (median age: 36 years (IQR: 30-45), male sex: 66%, genotype A/E: 16/84%, HBeAg-positive: 13%), the distribution of HBV DNA levels was undetectable

Journal Pre-proof

(42%), 50-1,999 IU/mL (35%), 2,000-199,999 IU/mL (11%), and ≥200,000 IU/mL (12%). The proportions eligible for antiviral therapy were 21% (AASLD), 20% (EASL), and 22% (APASL). HBcrAg-CLEIA was detected in 53%. HBcrAg-RDT was positive in 23%. The sensitivity and specificity of HBcrAg-RDT to diagnose clinically important HBcrAg-CLEIA levels were 73.3% and 100% for ≥3.6 $\log_{10}$ U/mL, 95.2% and 97.3% for ≥4.5 $\log_{10}$ U/ml, and 100% and 92.8 for ≥5.3 $\log_{10}$ U/ml, respectively. The sensitivity and specificity of HBcrAg-RDT to diagnose clinically important HBV DNA levels were 72.7% and 91.7% for ≥2,000 IU/ml, 86.7% and 88.7% for ≥20,000 IU/ml, and 91.4% and 86.3% for ≥200,000 IU/ml, respectively (Table). The sensitivity of HBcrAg-RDT was higher than HBeAg-EIA and comparable to HBcrAg-CLEIA (Table). In women of reproductive age (n=67), the sensitivity and specificity of HBcrAg-RDT to indicate viral loads ≥200,000 IU/ml were 100% and 87.5%, respectively. The performance of HBcrAg-RDT did not vary across the viral genotypes.

For the simplified algorithms using HBcrAg-RDT to indicate treatment eligibility (Table), the sensitivity and specificity of Model 1 (HBcrAg-RDT/ALT/FibroScan) were 96.6% and 83.2% for EASL, 93.2% and 86.7% for AASLD, and 90.5% and 96.8% for APASL, respectively. Model 2 (HBcrAg-RDT/ALT) performed less well than Model 1, but was comparable to TREAT-B (HBeAg-EIA/ALT).

We developed a novel point-of-care test detecting high HBcrAg levels and high viremia in serum, plasma, or whole blood. Its low production cost (US$<5), simple specimen preparation, no requirement for equipment/cold chains, operating temperature (39 °C), and rapid turnaround time (45 minutes), all favour its use at the point of care in LMICs. WHO recently recommends HBeAg

Journal Pre-proof

testing as an alternative to HBV DNA to determine eligibility for peripartum antiviral prophylaxis.[4] This recommendation was based on a meta-analysis of HBeAg performance showing pooled sensitivity of 88.2% and specificity of 92.6% for indicating viral loads ≥200,000 IU/mL.[10] These estimates, however, were mostly based on studies using laboratory-based immunoassays (EIA/CLEIA). In studies using RDTs, the pooled sensitivity was only 70.1%.[10] Compared to these, the performance of HBcrAg-RDT observed in Gambian women of childbearing age (sensitivity 100%, specificity 87.5%) is highly promising. Our study also suggested the usefulness of several HBV DNA-free algorithms with HBcrAg-RDT to determine treatment eligibility. Importantly, Model 2 (HBcrAg-RDT/ALT), which performs as well as TREAT-B (HBeAg-EIA/ALT), may provide additional benefits by enabling clinical management at primary care facilities without laboratory-based immunoassays.

As limitations, HBcrAg-RDT may be useful for initiating antiviral therapy, but not for monitoring treatment response. HBcrAg-RDT was only validated using stored sera from a single cohort. Further evaluation is warranted in other cohorts using different sample. In conclusion, HBcrAg-RDT is a simple, affordable, and reliable tool to identify highly viremic patients in LMICs.

Journal Pre-proof

References

1. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67:1560-1599.
2. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67:370-398.
3. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1-98.
4. WHO. Prevention of Mother-to-Child Transmission of Hepatitis B Virus: Guidelines on Antiviral Prophylaxis in Pregnancy. Geneva, Switzerland, 2020.
5. Testoni B, Lebossé F, Scholtes C, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol 2019;70:615-625.
6. Yoshida K, Desbiolles A, Feldman SF, et al. Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. Clin Gastroenterol Hepatol 2021;19:46-60.e8.
7. Shimakawa Y, Veillon P, Birguel J, et al. Residual risk of mother-to-child transmission of hepatitis B virus infection despite timely birth-dose vaccination in Cameroon (ANRS 12303): a single-centre, longitudinal observational study. Lancet Glob Heal 2022:1-9.
8. Shimakawa Y, Ndow G, Njie R, et al. Hepatitis B core-related antigen: An alternative to hepatitis B Virus DNA to assess treatment eligibility in Africa. Clin Infect Dis 2020;70:1442-1452.
9. Shimakawa Y, Njie R, Ndow G, et al. Development of a simple score based on HBeAg

Journal Pre-proof

and ALT for selecting patients for HBV treatment in Africa. J Hepatol 2018;69:776-784.

10. Boucheron P, Lu Y, Yoshida K, et al. Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis. Lancet Infect Dis 2021;21:85-96.

Journal Pre-proof

Journal Pre-proof

Table. Sensitivity and specificity of three antigen tests (HBcrAg-RDT, HBcrAg-CLEIA, and HBeAg-EIA) to discriminate clinically important HBV DNA levels and four simplified algorithms (Models 1-3 based on HBcrAg-RDT and TREAT-B) to select patients eligible for antiviral therapy in HBsAg-positive Gambian patients (N=284)

		All patients (N=284)		Subgroup analyses					
				Women of reproductive age (n=67)		Genotype A (n=38)		Genotype E (n=198)	
		Sen	Spe	Sen	Spe	Sen	Spe	Sen	Spe
To diagnose clinically important high HBV DNA levels									
Viral load ≥ 2 000 IU/ml	HBcrAg-RDT	72.7%	91.7%	87.5%	93.2%	72.7%	88.9%	74.1%	91.0%
	HBcrAg-CLEIA[a]	83.3%	83.9%	87.5%	81.4%	90.9%	70.4%	83.3%	84.7%
	HBeAg-EIA	47.7%	97.6%	50.0%	96.5%	50.0%	96.3%	48.1%	97.2%
Viral load ≥ 20 000 IU/ml	HBcrAg-RDT	86.7%	88.7%	100%	90.3%	87.5%	86.7%	88.9%	87.0%
	HBcrAg-CLEIA[b]	88.9%	90.4%	100%	91.9%	87.5%	86.7%	91.7%	89.5%
	HBeAg-EIA	61.4%	96.0%	60.0%	95.0%	71.4%	96.7%	61.1%	95.0%
Viral load ≥ 200 000 IU/ml	HBcrAg-RDT	91.4%	86.3%	100%	87.5%	83.3%	81.3%	93.1%	84.6%
	HBcrAg-CLEIA[c]	91.4%	93.2%	100%	93.8%	83.3%	84.4%	93.1%	92.9%
	HBeAg-EIA	70.6%	94.9%	66.7%	93.5%	100%	96.9%	65.5%	93.4%
To select HBV-infected patients eligible for antiviral therapy									
EASL 2017	Model 1 (HBcrAg-RDT, ALT, FS)[d]	96.6%	83.2%	100%	88.3%	90.9%	92.6%	97.7%	84.5%
	Model 2 (HBcrAg-RDT, ALT)[e]	87.3%	78.6%	83.3%	91.5%	80.0%	77.8%	87.8%	80.3%
	Model 3 (HBcrAg-RDT only)	72.4%	89.4%	85.7%	91.7%	54.5%	81.5%	81.4%	88.4%
	TREAT-B (HBeAg-EIA, ALT)[e]	81.5%	82.4%	83.3%	89.5%	66.7%	81.5%	85.4%	83.3%
AASLD 2018	Model 1 (HBcrAg-RDT, ALT, FS)[d]	93.2%	86.7%	100%	95.0%	84.6%	100%	95.2%	87.8%
	Model 2 (HBcrAg-RDT, ALT)[e]	87.5%	79.0%	83.3%	91.5%	83.3%	84.0%	87.5%	79.7%
	Model 3 (HBcrAg-RDT only)	69.5%	88.9%	85.7%	91.7%	61.5%	88.0%	76.2%	86.5%
	TREAT-B (HBeAg-EIA, ALT)[e]	81.8%	82.8%	83.3%	89.5%	72.7%	88.0%	85.0%	82.8%
APASL 2015	Model 1 (HBcrAg-RDT, ALT, FS)[d]	90.5%	96.8%	100%	100%	62.5%	96.7%	93.3%	96.7%
	Model 2 (HBcrAg-RDT, ALT)[e]	98.4%	83.6%	100%	90.2%	87.5%	75.9%	100%	84.7%

Journal Pre-proof

	Model 3 (HBcrAg-RDT only)	63.5%	88.2%	100%	90.3%	62.5%	80.0%	77.8%	88.2%
	TREAT-B (HBeAg-EIA, ALT)[e]	96.6%	87.9%	100%	88.1%	85.7%	82.8%	97.7%	87.8%

Abbreviations: AASLD, American Association for the Study of Liver Diseases; ALT, alanine aminotransferase; APASL, Asian Pacific Association for the Study of the Liver; EASL, European Association for the Study of the Liver; FS, FibroScan; HBcrAg-CLEIA, hepatitis B core-related antigen by chemiluminescence immunoassay; HBcrAg-RDT, hepatitis B core-related antigen by rapid diagnostic test; HBeAg-EIA, hepatitis B e antigen by enzyme immunoassay; TREAT-B, Treatment Eligibility in Africa for HBV.

[a] Cut-off level of 3.6 $\log_{10}$ U/mL was applied.

[b] Cut-off level of 4.5 $\log_{10}$ U/mL was applied.

[c] Cut-off level of 5.3 $\log_{10}$ U/mL was applied

[d] Significant fibrosis (Metavir ≥F2) and cirrhosis (F4) were defined as liver stiffness ≥7.9 and ≥9.5 kPa, respectively (Lemoine M et al., Gut 2016).

[e] Model 2, as well as TREAT-B, applied the cut-off of ≥2 points to indicate treatment eligibility.

Journal Pre-proof

Journal Pre-proof

Device



Principle



Procedure
(serum, plasma, whole blood)



Interpretation



Supplementary Figure. Device, principle, procedure and interpretation

Journal Pre-proof

Journal Pre-proof

Supplementary Table. Detection limit of HBcrAg-RDT using serum, plasma, and whole blood

HBcrAg levels (defined by the reference CLEIA)	% detected by HBcrAg-RDT		
	Serum	Plasma	Whole blood
5.2 log_{10} U/mL			100%
4.9 log_{10} U/mL			100%*
4.6 log_{10} U/mL	100%	100%	40%
4.3 log_{10} U/mL	95%*	100%*	0%
4.0 log_{10} U/mL	25%	20%	
3.7 log_{10} U/mL	0%	0%	

* The limit of detection was defined as the lowest concentration that was detected in ≥95% of 20 replicates (4.3 log_{10} U/mL for serum and plasma and 4.9 log_{10} U/mL for whole blood).

Journal Pre-proof